Reaction

Gingival Swelling reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,350 reports · 109 co-occurring drugs

As of the last recalculation, Gingival Swelling appears in 4,350 FAERS reports alongside 109 co-occurring drug terms. The strongest observed disproportionality signal is EXEMESTANE (PRR 16.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Exemestane	73	16.6	16.6
Chlorhexidine Gluconate	29	15.3	15.3
Extended Phenytoin Sodium	42	12.1	12.1
Zoledronic Acid	88	10.7	10.7
Drs. Clotrimazole	21	8.7	8.7
Family Wellness Clotrimazole	21	8.7	8.7
Clotrimazole Topical	21	8.7	8.7
Risedronate Sodium	53	8.2	8.3
Clotrimazole	21	8.2	8.2
Fulvestrant	50	7.3	7.3
Bicalutamide	23	7.3	7.3
Anastrozole	54	7.1	7.1
Voclosporin	12	6.6	6.6
Buprenorphine Hydrochloride, Naloxone Hydrochloride	32	6.4	6.4
Gentamicin	17	6.2	6.2
Goserelin	17	6.1	6.1
Sunitinib Malate	49	6.0	6.0
Nicotine Polacrilex	47	5.9	5.9
Alendronate Sodium	116	5.6	5.6
Hydrocortisone Sodium Succinate	11	5.6	5.6
Letrozole	71	5.6	5.6
Phenytoin	23	5.3	5.3
Denosumab	215	5.3	5.3
Gentamicin Sulfate	17	5.2	5.2
Anastrozole Tablets	23	5.2	5.2
Bisacodyl	15	5.1	5.1
Cimetidine	10	5.0	5.0
Romosozumab-Aqqg	14	4.9	5.0
Cabozantinib	49	4.9	4.9
Bisacodyl Suppositories	13	4.8	4.8
Eltrombopag Olamine	23	4.8	4.8
Amlodipine	257	4.8	4.8
Biscodyl	13	4.8	4.8
Clarithromycin	34	4.8	4.8
Meperidine Hydrochloride	9	4.7	4.7
Amlodipine Besylate And Benazepril Hydrochloride	9	4.7	4.7
Everolimus	49	4.6	4.7
Metronidazole Topical	41	4.1	4.1
Metronidazole	53	4.0	4.0
Raloxifene Hydrochloride	12	3.9	3.9
Amoxicillin	61	3.9	3.9
Melphalan Hydrochloride	20	3.8	3.8
Thalidomide	29	3.8	3.8
Fexofenadine	13	3.8	3.8
Carisoprodol	15	3.8	3.8
Calcium	114	3.7	3.7
Lanreotide Acetate	6	3.7	3.7
Methimazole	6	3.7	3.7
Epoetin Alfa	9	3.6	3.6
Oseltamivir	6	3.6	3.6
Melphalan	17	3.6	3.6
Fesoterodine Fumarate	8	3.5	3.5
Pertuzumab	20	3.5	3.5
Ribociclib	23	3.5	3.5
Lisinopril And Hydrochlorothiazide	7	3.3	3.3
Amlodipine Besylate	98	3.3	3.3
Azelastine	12	3.2	3.2
Niraparib	14	3.0	3.0
Phenobarbital	9	3.0	3.0
Prochlorperazine	17	2.9	2.9
Multivitamin	30	2.9	2.9
Losartan Potassium	47	2.9	2.9
Peginterferon Alfa-2A	32	2.8	2.8
Ado-Trastuzumab Emtansine	5	2.8	2.8
Palbociclib	56	2.8	2.8
Pitavastatin Calcium	6	2.8	2.8
Letrozole Tablets	28	2.8	2.8
Estradiol Gel 0.1%	26	2.8	2.8
Estradiol Transdermal	26	2.8	2.8
Trastuzumab	39	2.7	2.7
Axitinib	11	2.7	2.7
Oxycodone And Acetaminophen	13	2.7	2.7
Lenvatinib	18	2.6	2.6
Amlodipine Besylate And Valsartan	6	2.6	2.6
Zonisamide	8	2.6	2.6
Capecitabine	49	2.6	2.6
Nicotine	21	2.5	2.5
Dorzolamide Hydrochloride And Timolol Maleate	4	2.4	2.4
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	2.3	2.3
Icosapent Ethyl	4	2.2	2.2
Selinexor	4	2.2	2.2
Glecaprevir And Pibrentasvir	5	2.2	2.2
Brivaracetam	4	2.1	2.1
Fluticasone Propionate And Salmeterol	18	2.1	2.1
Oseltamivir Phosphate	10	2.0	2.0
Botulinum Toxin Type A	5	1.9	1.9
Docetaxel Anhydrous	27	1.9	1.9
Docetaxel	27	1.9	1.9
Varenicline Tartrate	32	1.9	1.9
Rifaximin	8	1.8	1.8
Trifluridine And Tipiracil	4	1.8	1.8
Pazopanib Hydrochloride	10	1.8	1.8
Umeclidinium Bromide And Vilanterol Trifenatate	6	1.7	1.7
Glycerin, Lidocaine	5	1.7	1.7
Vigabatrin	5	1.6	1.6
Docosanol	5	1.6	1.6
Rucaparib	3	1.6	1.6
Nirmatrelvir And Ritonavir	16	1.4	1.4
Bimekizumab	6	1.3	1.3
Osimertinib	9	1.3	1.3
Medroxyprogesterone Acetate	13	1.2	1.2
Pomalidomide	26	1.2	1.2
Abemaciclib	5	1.2	1.2
Lifitegrast	4	1.2	1.2
Lenalidomide	103	1.2	1.2
Abaloparatide	7	1.1	1.1
Rimegepant Sulfate	3	1.1	1.1
Dupilumab	67	0.7	0.7
Pimavanserin Tartrate	5	0.4	0.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.